318 related articles for article (PubMed ID: 29305518)
21. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma.
Bozzetti C; Negri FV; Lagrasta CA; Crafa P; Bassano C; Tamagnini I; Gardini G; Nizzoli R; Leonardi F; Gasparro D; Camisa R; Cavalli S; Silini EM; Ardizzoni A
Br J Cancer; 2011 Apr; 104(9):1372-6. PubMed ID: 21487407
[TBL] [Abstract][Full Text] [Related]
22. Two updates on oesophagogastric junction adenocarcinoma from the fifth WHO classification: Alteration of definition and emphasis on HER2 test.
Li Y; Li J; Li J
Histol Histopathol; 2021 Mar; 36(3):339-346. PubMed ID: 33377175
[TBL] [Abstract][Full Text] [Related]
23. Colorectal adenocarcinoma with enteroblastic differentiation: a clinicopathological study of five cases.
Murakami T; Yao T; Yatagai N; Yamashiro Y; Saito T; Sakamoto N; Nagahara A
Histopathology; 2020 Jan; 76(2):325-332. PubMed ID: 31429980
[TBL] [Abstract][Full Text] [Related]
24. [AFP-producing gastric cancer and hepatoid gastric cancer].
Wang YK; Zhang XT
Zhonghua Zhong Liu Za Zhi; 2017 Nov; 39(11):801-807. PubMed ID: 29151285
[TBL] [Abstract][Full Text] [Related]
25. Evidence for hepatocellular differentiation in alpha-fetoprotein-negative gastric adenocarcinoma with hepatoid morphology: a study with in situ hybridisation for albumin mRNA.
Supriatna Y; Kishimoto T; Uno T; Nagai Y; Ishikura H
Pathology; 2005 Jun; 37(3):211-5. PubMed ID: 16175893
[TBL] [Abstract][Full Text] [Related]
26. Human epidermal growth factor receptor-2 in oesophageal cancers: an observational study.
Al-Momani H; Barnes R; El-Hadi A; Shah R; Lewis WG; Edwards P
World J Gastroenterol; 2012 Nov; 18(44):6447-51; discussion p.6450. PubMed ID: 23197890
[TBL] [Abstract][Full Text] [Related]
27. [Immunohistochemical assessment of HER2 expression in gastric cancer. A clinicopathologic study of 93 cases].
Alvarado-Cabrero I; Gil-Hernández S; Ruelas-Perea A; Villaverde-Rodríguez D; Montes-Ochoa JR; Medrano-Guzmán R
Cir Cir; 2017; 85(6):504-509. PubMed ID: 28069112
[TBL] [Abstract][Full Text] [Related]
28. Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival.
He XX; Ding L; Lin Y; Shu M; Wen JM; Xue L
J Clin Pathol; 2015 May; 68(5):374-80. PubMed ID: 25731189
[TBL] [Abstract][Full Text] [Related]
29. Serum HER2 levels and HER2 status in tumor cells in advanced gastric cancer patients.
Sasaki T; Fuse N; Kuwata T; Nomura S; Kaneko K; Doi T; Yoshino T; Asano H; Ochiai A; Komatsu Y; Sakamoto N; Ohtsu A
Jpn J Clin Oncol; 2015 Jan; 45(1):43-8. PubMed ID: 25378649
[TBL] [Abstract][Full Text] [Related]
30. HER2 in gastric cancer: comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays.
Abrahão-Machado LF; Jácome AA; Wohnrath DR; dos Santos JS; Carneseca EC; Fregnani JH; Scapulatempo-Neto C
World J Gastroenterol; 2013 Oct; 19(38):6438-46. PubMed ID: 24151362
[TBL] [Abstract][Full Text] [Related]
31. Significance of TFF3 protein and Her-2/neu status in patients with gastric adenocarcinoma.
Xu CC; Yue L; Wei HJ; Zhao WW; Sui AH; Wang XM; Qiu WS
Pathol Res Pract; 2013 Aug; 209(8):479-85. PubMed ID: 23822993
[TBL] [Abstract][Full Text] [Related]
32. [Gastric adenocarcinoma with enteroblastic differentiation and elevated serum alpha fetoprotein].
Li QZ; Zhao HB; Ban N; Wang Q; Zhang JJ; Ding SN; Li HH; Zhou ZH
Zhonghua Bing Li Xue Za Zhi; 2020 Sep; 49(9):886-890. PubMed ID: 32892552
[No Abstract] [Full Text] [Related]
33. HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison.
Koopman T; Smits MM; Louwen M; Hage M; Boot H; Imholz AL
J Cancer Res Clin Oncol; 2015 Aug; 141(8):1343-51. PubMed ID: 25544671
[TBL] [Abstract][Full Text] [Related]
34. A large cohort of consecutive patients confirmed frequent HER2 positivity in gastric carcinomas with advanced stages.
Cho J; Jeong J; Sung J; Sung CO; Kim KM; Park CK; Choi MG; Sohn TS; Bae JM; Kim S
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S477-84. PubMed ID: 23274580
[TBL] [Abstract][Full Text] [Related]
35. An Integrative Morphomolecular Classification System of Gastric Carcinoma With Distinct Clinical Outcomes.
Tsai JH; Jeng YM; Chen KH; Lee CH; Yuan CT; Liau JY
Am J Surg Pathol; 2020 Aug; 44(8):1017-1030. PubMed ID: 32568823
[TBL] [Abstract][Full Text] [Related]
36. Differing deregulation of HER2 in primary gastric cancer and synchronous related metastatic lymph nodes.
Kochi M; Fujii M; Masuda S; Kanamori N; Mihara Y; Funada T; Tamegai H; Watanabe M; Suda H; Takayama T
Diagn Pathol; 2013 Nov; 8():191. PubMed ID: 24261710
[TBL] [Abstract][Full Text] [Related]
37. Gastric hepatoid adenocarcinomas are a genetically heterogenous group; most tumors show chromosomal instability, but MSI tumors do exist.
Tsuruta S; Ohishi Y; Fujiwara M; Ihara E; Ogawa Y; Oki E; Nakamura M; Oda Y
Hum Pathol; 2019 Jun; 88():27-38. PubMed ID: 30946937
[TBL] [Abstract][Full Text] [Related]
38. Trastuzumab combined with docetaxel-based regimens in previously treated metastatic gastric cancer patients with HER2 over-expression.
Dai GH; Shi Y; Chen L; Lv YL; Zhong M
Hepatogastroenterology; 2012; 59(120):2439-44. PubMed ID: 22534547
[TBL] [Abstract][Full Text] [Related]
39. Potential prognostic significance of p185(HER2) overexpression with loss of PTEN expression in gastric carcinomas.
Im SA; Lee KE; Nam E; Kim DY; Lee JH; Han HS; Seoh JY; Park HY; Cho MS; Han WS; Lee SN
Tumori; 2005; 91(6):513-21. PubMed ID: 16457151
[TBL] [Abstract][Full Text] [Related]
40. Double cancer of the stomach, one AFP-producing tumor.
Hyodo T; Kawamoto R
J Gastroenterol; 1996 Dec; 31(6):851-4. PubMed ID: 9027651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
